Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

Schumacher is stepping down by mutual agreement on Saturday, before leaving the company on May 31. Japanese trading-house stocks rose sharply after Warren Buffett said Berkshire Hathaway's stakes in ...

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

UnitedHealth Group, Alphabet, Hims & Hers Health, Salesforce, and Johnson & Johnson are the five Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. These companies had ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...